Ittai Harel is a General Partner of Pitango. Before joining Pitango, Mr. Harel headed up Corporate Development at Nektar Therapeutics (NASDAQ: NKTR) and served as Executive Vice President at IDGene Pharmaceuticals. He also served as head of business development at IDEXX Laboratories (NASDAQ: IDXX). Mr. Harel holds a B.Sc. in Chemical Engineering and Biotechnology from Ben Gurion University, and an MBA from the MIT Sloan School of Management.
Robert Taub has been an entrepreneur in the biopharmaceutical and medical technology fields for more than four decades. He is an investor and co-founder/ founder of life science companies worldwide, including in Israel. More recently, in 2009, he co-founded Nyxoah S.A, an implantable device company to treat obstructive sleep apnea. In 1995, he founded and served as the chief executive officer, president and director at Omrix Biopharmaceuticals, Inc. where he led the company’s April 2006 NASDAQ IPO and eventual sale to ETHICON, Johnson and Johnson in December 2008 for $432 million. In 1983 Mr. Taub co-founded Octapharma, a Swiss plasma fractionation and pharmaceutical company, which successfully introduced innovative plasma derivative products to the market. He co-managed the company until 1995. Robert Taub has made several investments in the biotech/MEDTECH sector taking an active board position in most cases. In particular, he is currently the executive chairman of Neuroderm ltd., a company developing products to treat Parkinson’s and other neuro-degenerative diseases. Robert Taub holds a B.A. in languages from the University of Antwerp and an M.B.A. from INSEAD (the European Institute of Business Administration) in Fontainebleau, France.
Eli Frydman is a Managing Director – Healthcare for Aurum Ventures MKI. Before joining Aurum, Dr. Frydman served as the Chief Business Officer of FutuRx, the drug development incubator established by J&J, Orbimed and Takeda. Prior to that, he served for 10 years as the COO of Aposense Ltd., (TASE: APOS), with responsibilities for business development, operations and finance. Before joining Aposense, Dr. Frydman served as a Senior Business Development manager at GE Healthcare Europe (based in France), doing healthcare M&A across Europe. Mr. Frydman holds an MBA from the Ecole des Ponts, in Paris, and a PhD in Chemistry (nanotechnology) from the Weizmann Institute of Science.
Orahn is the CTO and co-founder of LifeBond. Since founding LifeBond in 2007, Orahn has been leading the company’s development efforts ever since. Previously, he gained expertise in applied biomedical & biomechanical research while a researcher at the IDF Institute for Military Physiology. He holds a M.Sc. in Biomedical Engineering from the Technion in Israel where he studied implantable polymer biomechanics. Orahn also earned a B.Sc. in Biomedical Engineering at Columbia University, where he was involved in applied biomechanics research at the Department of Orthopedic Surgery for several years.
Gideon is the CEO & President of LifeBond. Gideon has more than 20 years of experience in technology and life science company management. Prior to joining LifeBond, he was the general manager of Lumenis Vision and corporate EVP. Early in his career he co-founded Galil Medical and served as a turnaround manager at the Wertheimer Group. Gideon was also a venture partner at the Ofer High-Tech Group. He holds a MSc in mechanical engineering and computer science from the Technion, Israel.